RT Journal Article
SR Electronic
A1 Helwick, Caroline
T1 EVEREST: Modest Gains from Tolvaptan in Heart Failure
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 1
SP 15
OP 16
DO 10.1177/155989770700700106
UL http://mdc.sagepub.com/content/7/1/15.2.abstract
AB Results from the EVEREST trial indicated that in patients with acute decompensated heart failure, tolvaptan, an oral nonpeptide vasopressin V2-receptor blocker, did not reduce mortality or hospitalizations but did provide modest symptomatic relief.